Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Anti-neuroinflammation effect of zonisamide in early Parkinson’s disease: A chronological PET study

Author:Matsudaira, Takashi   Terada, Tatsuhiro   Bunai, Tomoyasu   Hashizume, Takanori   Yokokura, Masamichi   Takashima, Hirotsugu   Konishi, Takashi   Obi, Tomokazu   Ouchi, Yasuomi   

Session Name:P13: Movement Disorders: Non Surgical Therapeutics in Parkinson's Disease 1  

Topic:Movement Disorders  

Program Number:P13.010  

Author Institution:Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan  Osaka Ohtani University, Osaka, Japan  Hamamatsu University School of Medicine, Hamamatsu, Japan  Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan  NHO Shizuoka Institute of Epilepsy and Neurological disorders, Shizuoka, Japan  

Satralizumab Treatment in Adult Patients With AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series

Author:Abboud, Hesham   Steingo, Brian   Vargas, Diana   Patel, Julie   Nealon, Nancy   Willis, Mary Alissa   Mao-Draayer, Yang   Khaitov, Dmitry   Avila Ornelas, Jose   Subei, Adnan   Reed, Clifford   Ferayorni, Lisa   Laucirica, Xavier   Gholizadeh, Shervin   

Session Name:P13: Autoimmune Neurology: NMOSD / MOGAD / Optic Neuritis  

Topic:Autoimmune Neurology  

Program Number:P13.010  

Author Institution:University Hospitals Cleveland Medical Center, Cleveland, OH  Infinity Clinical Research, Sunrise, FL  Emory University School of Medicine, Atlanta, GA  Emory University School of Medicine and Emory University Hospital Midtown, Atlanta, GA  Weill Cornell Medicine, New York, NY  University of Mississippi Medical Center, Jackson, MS  University of Michigan School of Medicine, Ann Arbor, MI  Lehigh Valley Health Network, Allentown, PA  HIMA Caguas Multiple Sclerosis Center, Caguas, PR  Memorial Healthcare System, Hollywood, FL  Reading Hospital, West Reading, PA  Genentech, Inc., South San Francisco, CA  

The MS-LINK Outcomes Study Cohort: Study design and a descriptive analysis of baseline key PROs, disease, and sociodemographic characteristics

Author:English, Jeffrey   Tornatore, Carlo   Riser, Emily   Pardo, Gabriel   Freeman, Leorah   Sloane, Jacob   Piette, Elizabeth   Caon, Christina   Livingston, Terrie   

Session Name:P13: MS Clinical Assessments and Outcome Measures  

Topic:MS and Inflammatory Disease  

Program Number:P13.010  

Author Institution:Multiple Sclerosis Center of Atlanta, Atlanta, GA  MedStar Georgetown University Hospital, Washington, DC  Alabama Neurology Associates, Birmingham, AL  Oklahoma Medical Research Foundation, Oklahoma City, OK  Dell Medical School, The University of Texas at Austin, Austin, TX  Beth Israel Deaconess Medical Center, Boston, MA  EMD Serono, Inc., Rockland, MA  

Initiating dopamine agonists rather than levodopa in early Parkinson’s disease does not delay the need for DBS.

Author:Olszewska, Diana Angelika   Fasano, Alfonso   Munhoz, Renato P   Ramirez Gomez, Carolina Candelaria   Lang, Anthony E   

Session Name:P13: Movement Disorders: Non Surgical Therapeutics in Parkinson's Disease 1  

Topic:Movement Disorders  

Program Number:P13.011  

Author Institution:Toronto Western Hospital, Toronto, ON, Canada  Hospital General Regional #1 Carlos Mac Gregor Sanchez, Mexico City, Mexico  

Effect of Eptinezumab on Utility Scores in Patients with Migraine: Results from the DELIVER Study

Author:Jonsson, Linus   Regnier, Stephane A   Kymes, Steven   Talon, Brian   Awad, Susanne F   Lee, Xin Ying   Goadsby, Peter J   

Session Name:P13: Headache: Towards Precision Medicine 3  

Topic:Headache  

Program Number:P13.011  

Author Institution:Department for Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden  H. Lundbeck A/S, Copenhagen, Denmark  Lundbeck LLC, Deerfield, IL  NIHR-King’s Clinical Research Facility, King’s College London, London, United Kingdom